[Federal Register Volume 65, Number 28 (Thursday, February 10, 2000)]
[Notices]
[Pages 6613-6614]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 00-3014]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration


Nonclinical Studies Subcommittee of the Advisory Committee for 
Pharmaceutical Science; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

    This notice announces a forthcoming meeting of a public advisory 
committee of the Food and Drug Administration (FDA). The meeting will 
be open to the public.

    Name of Committee: Nonclinical Studies Subcommittee of the 
Advisory Committee for Pharmaceutical Science (formerly the Generic 
Drugs Advisory Committee).
    General Function of the Committee: To provide advice and 
recommendations to the agency on FDA regulatory issues.
    Date and Time: The meeting will be held on March 9, 2000, 8:30 
a.m. to 5:30 p.m.
    Location: Center for Drug Evaluation and Research conference 
room 1066, 5630 Fishers Lane, Rockville, MD.
    Contact Person: Kimberly L. Topper, Center for Drug Evaluation 
and Research (HFD-21), Food and Drug Administration, 5600 Fishers 
Lane Rockville, MD 20857, 301-827-7001, e-mail: 
<a href="/cdn-cgi/l/email-protection#60342f303025322b20030405124e0604014e070f16"><span class="__cf_email__" data-cfemail="abffe4fbfbeef9e0ebc8cfced985cdcfca85ccc4dd">[email protected]</span></a>, or FDA Advisory Committee Information Line, 1-
800-741-8138 (301-443-0572 in the Washington, DC area), code 12539. 
Please call the Information Line for up-to-date information on this 
meeting.
    Agenda: The subcommittee meeting will discuss collaborative 
approaches to scientific research issues of common interest to the 
pharmaceutical industry, universities, the public, and FDA. Specific 
areas of focus will be in the nonclinical studies areas of: (1) 
Interspecies biomarkers of toxicity and (2) noninvasive imaging.
    Procedure: Interested persons may present data, information, or 
views, orally or in writing, on issues pending before the committee. 
Written submissions may be made to the contact person by February 
25, 2000. Oral presentations from the public will be scheduled 
between approximately 1 p.m. to 2 p.m. Time allotted for each 
presentation may be limited. Those desiring to make formal oral 
presentations should notify the contact person before February 25, 
2000, and

[[Page 6614]]

submit a brief statement of the general nature of the evidence or 
arguments they wish to present, the names and addresses of proposed 
participants, and an indication of the approximate time requested to 
make their presentation.
    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. app. 2).

    Dated: February 2, 2000.
Linda A. Suydam,
Senior Associate Commissioner for Policy.
[FR Doc. 00-3014 Filed 2-9-00; 8:45 am]
BILLING CODE 4160-01-F


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>